NRX Pharmaceuticals, Inc. Payments to Acquire Productive Assets
NRX Pharmaceuticals, Inc. (NRXP) reported Payments to Acquire Productive Assets of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2025-05-15
- NRX Pharmaceuticals, Inc. payments to acquire productive assets for the quarter ending 2025-03-31 was $0.00.
- NRX Pharmaceuticals, Inc. payments to acquire productive assets for the quarter ending 2024-12-31 was $0.00.
- NRX Pharmaceuticals, Inc. payments to acquire productive assets for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. payments to acquire productive assets for the quarter ending 2024-06-30 was $0.00.
- NRX Pharmaceuticals, Inc. payments to acquire productive assets for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- NRX Pharmaceuticals, Inc. payments to acquire productive assets for fiscal 2023 was $3.00K, a 70.00% decline from fiscal 2022.
- NRX Pharmaceuticals, Inc. payments to acquire productive assets for fiscal 2022 was $10.00K, a 42.86% increase from fiscal 2021.
- NRX Pharmaceuticals, Inc. payments to acquire productive assets for fiscal 2021 was $7.00K, a 250.00% increase from fiscal 2020.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 6 month as first filed | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 9 month as first filed | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-05-15 | $0.00 derived: sum of 3 quarters · filed 2025-05-15 | $0.00 derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-14 | $0.00 derived: sum of 3 quarters · filed 2025-03-14 | $0.00 10-K · filed 2025-03-14 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | -$1.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | -$1.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | -$1.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.00K derived: sum of 3 quarters · filed 2025-05-15 | -$1.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $1.00K derived: sum of 2 quarters · filed 2025-03-14 | -$1.00K derived: sum of 3 quarters · filed 2025-03-14 | $3.00K 10-K · filed 2025-03-14 | ||
| 2023-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $4.00K 10-Q · filed 2024-11-14 | $3.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.00K 10-Q · filed 2024-08-14 | $1.00K derived: sum of 3 quarters · filed 2024-08-14 | $6.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $4.00K 10-Q · filed 2024-05-14 | $3.00K derived: sum of 2 quarters · filed 2024-05-14 | $8.00K derived: sum of 3 quarters · filed 2024-05-14 | $11.00K derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $4.00K derived: sum of 2 quarters · filed 2024-03-29 | $7.00K derived: sum of 3 quarters · filed 2024-03-29 | $10.00K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $8.00K derived: sum of 2 quarters · filed 2023-11-14 | $11.00K 10-Q · filed 2023-11-14 | $11.00K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $6.00K 10-Q · filed 2023-08-14 | $6.00K derived: sum of 3 quarters · filed 2023-08-14 | $10.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $3.00K 10-Q · filed 2023-05-15 | $3.00K derived: sum of 2 quarters · filed 2023-05-15 | $7.00K derived: sum of 3 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $4.00K derived: sum of 2 quarters · filed 2023-03-31 | $7.00K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $7.00K 10-Q · filed 2022-11-14 | $6.61K 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $3.00K 10-Q · filed 2022-08-15 | $2.78K 10-Q · filed 2021-08-16 | ||||
| 2020-12-31 | $2.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |